155 results
Page 7 of 8
8-K
EX-99.2
9cik0 zjwnsf6f6
22 Jul 19
Regulation FD Disclosure
9:29am
8-K
EX-1.1
fpm66pdt95 or1
20 May 19
Entry into a Material Definitive Agreement
9:28am
424B5
ztut8
20 May 19
Prospectus supplement for primary offering
9:18am
8-K
EX-99.1
damod10h
20 May 19
BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
9:04am
8-K
EX-99.2
i1r57mut
20 May 19
BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
9:04am
8-K
EX-99.1
dsia0i3
7 May 19
BioXcel Therapeutics Reports First Quarter 2019 Results and Provides Business Update
8:17am
8-K
EX-99.1
mbktexh
1 Apr 19
BioXcel Therapeutics Showcases Data on BXCL701 in Combination with OX40 Agonist in Late-breaking Poster Presentation at AACR Annual Meeting
4:08pm
8-K
EX-99.1
pu7r52j qmie9sv5
25 Mar 19
Other Events
4:45pm
S-3
3ng zg10szf
14 Mar 19
Shelf registration
4:45pm
10-K
rqd814qfygvsxn3s0aqq
12 Mar 19
Annual report
12:00am
8-K
EX-99.1
b5hx0f7b jn
11 Mar 19
BioXcel Therapeutics Announces Late Breaking Data Presentation at AACR 2019 Annual Meeting
4:38pm
8-K
EX-99.1
jfmgvyf1
7 Mar 19
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2018 Quarterly Results and Provides Business Update
4:42pm
8-K
EX-99.1
thy9p3qozchn0tvfi
4 Mar 19
Other Events
4:19pm
8-K
EX-99.1
r3ssdah62yr
4 Feb 19
Other Events
5:03pm
8-K
EX-99.2
4r2x12 54
3 Jan 19
Regulation FD Disclosure
4:16pm
8-K
EX-99.1
aakfmmxuqks86tsh7o
27 Dec 18
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation
4:11pm
8-K
EX-99.1
oquka8s tvk
20 Dec 18
BioXcel Therapeutics Doses First Subjects in Pharmacokinetic (Bioavailability) and Safety Study of BXCL501 for the Acute Treatment of Agitation
5:08pm
8-K
EX-99.1
09zj59 vb
12 Dec 18
BioXcel Therapeutics Announces FDA Acceptance of IND for Lead
9:05am